Development and Evaluation of a PSMA-Targeted Nanosystem Co-Packaging Docetaxel and Androgen Receptor siRNA for Castration-Resistant Prostate Cancer Treatment

• 主要な著者: Yingying Zhang (著者), Hongxia Duan (著者), Heming Zhao (著者), Lingling Qi (著者), Yanhong Liu (著者), Zheao Zhang (著者), Chao Liu (著者), Liqing Chen (著者), Mingji Jin (著者), Youyan Guan (著者), Zhonggao Gao (著者), Wei Huang (著者)
• フォーマット: 図書
• 出版事項: MDPI AG, 2022-04-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Primary prostate cancer (PC) progresses to castration-resistant PC (CRPC) during androgen deprivation therapy (ADR) in early stages of prostate cancer. Thus, rather than blocking the androgen-related pathway further, docetaxel (DTX)-based therapy has become the most effective and standard first-line...